Returning? Returning? Begin where you left off. If you have already completed part of the survey, you may continue where you left off. All you need is the return code given to you previously. Click the link below to begin entering your return code and continue the survey. Continue the survey A A A

DAY 1

Thursday, November 9, 2023   10:00 am - 4:00 pm  
Barbara Davis Center, Main Conference Room 2104
1775 Aurora Court

10:00-10:05 Welcome & Announcements (Marian Rewers, Denver, USA)

 

SESSION 1: COST-EFFECTIVENESS OF POPULATION SCREENING FOR T1D

10:05-10:20    Health Economics of T1D Screening      (R. Brett McQueen, Denver, USA)

10:20-10:35    Computational Framework for T1D Screening Optimization   (Gonçalo Leiria, Denver, USA)

10:35-10:50    Comparison of T1D Risk Models              (Lauric Ferrat, Exeter, the U.K.)

10:50-11:00    Panel discussion  

 

SESSION 2: COMBINED SCREENING FOR T1D AND OTHER PEDIATRIC DISEASES

11:00-11:15    Scandinavian Perspective                    (Daniel Agardh, Malmo, Sweden)

11:15-11:30    ASK Perspective                                      (Marisa Stahl and Edwin Liu, Aurora, USA)

11:30-11:45    Early Check Study                                   (Lisa Gehtland, RTI International, Durham, USA)

11:45-12:00    Panel discussion  

12:00-12:30    Lunch

 

SESSION 3: PRACTICAL ASPECTS OF SCREENING FOR PRE-SYMPTOMATIC T1D

12:30-12:45   Lessons from ASK                                               (Crystal Silva and Cristy Geno Rasmussen, Denver)

12:45-1:00     Stakeholders' engagement in screening      (Holly O'Donnell, Denver)

1:00-1:15       Screening in underserved populations        (Sonja O'Leary, Denver)                          

1:15-1:30       EPIC customization                                            (Amber Corr and Brigitte Frohnert, Denver)

1:30-1:45       Panel discussion

1:45-2:00       Break

 

SESSION 4: PRACTICAL ASPECTS OF MONITORING AND EDUCATION IN PRE-SYMPTOMATIC T1D            

2:00-2:20       Monitoring within a health care system    (Kurt Griffin, Sanford Health, Sioux Falls)

2:20-2:40       Monitoring by a tertiary care center          (Kim Bautista and Patricia Gesualdo, Denver)

2:40-3:00       Enrollment into clinical trials                       (Hali Broncucia and Andrea Steck, Denver)

3:00-3:20       Transition from research to clinical care   (Lexie Chesshir and Kimber Simmons, Denver)

3:20-4:00       Panel discussion

 

DAY 2

Friday, November 10, 2023    8:00am - 4:40 pm  
Anschutz Health Sciences Building, Room 2010/2011
1890 North Revere Court

8:00-8:05       Welcome & Announcements (Marian Rewers, Denver, USA)

 

SESSION 5: PRIORITIES AND CHALLENGES IN POPULATION SCREENING FOR T1D

8:05-9:00       Sanjoy Dutta and Esther Latres, JDRF, New York

Gina Agiostratidou and Anne Koralova, Helmsley Charitable Trust, New York

Beena Akolkar, NIDDK, NIH, Bethesda

 

SESSION 6:  REPORTS FROM CURRENT GENERAL POPULATION SCREENING PROGRAMS

9:00-9:30        Fr1da and EDENT1FI                                      (Peter Achenbach, Munich, Germany)

9:30-9:50       TRIAD & other Scandinavian programs    (Daniel Agardh, Malmo, Sweden)

9:50-10:10     Australian National Screening Pilot         (Kirstine Bell, Sydney, Australia)

10:10-10:30   CANscreen                                                       (Diane Wherrett, Toronto, Canada)

10:30-10:45   Break

 

10:45-11:00    Autoimmunity Screening for Kids (ASK)   (Cristy Geno Rasmussen, Denver, USA)

11:00-11:15    T1Detect                                                            (Anastasia Albanese-O'Neill, JDRF, USA)

11:15-11:30    PrIMeD: in-home screening for T1D          (Stephen Rich, Charlottesville, USA)

11:30-11:45    PLEDGE, Sanford Health                               (Kurt Griffin, Sioux Falls, USA)

11:45-12:00    CASCADE                                                           (William Hagopian, Seattle, USA)

12:15-12:30    Panel discussion

12:30-1:00      Lunch

 

SESSION 7: STANDARDIZATION OF IMMUNE MARKERS FOR SCREENING AND CONFIRMATION

1:00-1:20       Definition of challenges                             (Peter Achenbach, Munich, Germany)

1:20-1:40       IASP Perspective                                          (Vito Lampasona, Milan, Italy)

1:40-2:00       Multiplexing                                                  (Liping Yu, Denver, USA)

2:00-2:30       Panel discussion 

2:30-2:45       Break

 

SESSION 8: GUIDELINES FOR MONITORING AND EDUCATION IN PRE-SYMPTOMATIC T1D

2:45-3:05       Consensus building                                   (Linda DiMeglio, Indianapolis, USA)

3:05-3:25       Monitoring of children                             (Kimber Simmons, Denver, USA)

3:25-3:45       Monitoring of adults                                (Rifka Schulman-Rosenbaum, New York, USA)

3:45-4:05       Education                                                    (Brigitte Frohnert, Denver, USA)

4:05-4:25       Psychological support                             (Kimberly Driscoll, Gainesville, USA)

4:25-4:40       Panel discussion

4:40                Adjourn

 

This program was developed independently by the Barbara Davis Center for Diabetes and supported in part by educational grants from Sanofi US and the Children's Diabetes Foundation.

You have selected an option that triggers this survey to end right now.

To save your responses and end the survey, click the 'End Survey' button below. If you have selected the wrong option by accident and/or wish to return to the survey, click the 'Return and Edit Response' button.